insights_auto
Sebab LYEL menurun 5.05%?
Terokai Dengan Lebih Terperincichevron_right
LYEL:NASDAQ
Lyell Immunopharma Inc
USD 8.27
arrow_downward
-5.05%(-0.44) 1H
12 Okt, 4:00:01 PTG GMT-4 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk LYEL...
Buka
USD 8.63
Tinggi
USD 8.69
Rendah
USD 8.23
Permodalan Pasaran
202.66J
Purata volum
133.44K
Volum
100.33K
tgi 52 mgu
USD 45.00
rdh 52 mgu
USD 8.21
EPS
-USD 12.01
Beta
-0.03
Syer tertunggak
24.50J
Bilangan pekerja
161
Buka
USD 8.63
Tinggi
USD 8.69
Rendah
USD 8.23
Permodalan Pasaran
202.66J
Purata volum
133.44K
Volum
100.33K
tgi 52 mgu
USD 45.00
rdh 52 mgu
USD 8.21
EPS
-USD 12.01
Beta
-0.03
Syer tertunggak
24.50J
Bilangan pekerja
161
Cerita berita
Daripada sumber web dan rakan kongsi berita
Invezz
·
40 minit lalu
Dow naik 198 mata, saham AS bercampur menjelang keputusan pendapatan
Invezz
·
8 jam lalu
3 pemangkin utama untuk Indeks S&P 500 minggu ini: bon, musim laporan pendapatan, CPI
Invezz
·
7 jam lalu
Dow Jones dibuka 190 mata lebih tinggi, pelabur memerhati pendapatan bank dan inflasi
GlobeNewswire
·
56 minit lalu
LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Profil
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
Perihal Lyell Immunopharma Inc
CEO-
Pekerja161
Diasaskan2018
Ibu pejabatSouth San Francisco, California, Amerika Syarikat
Sektor-
Laman weblyell.com